$6.90−0.35 (−4.83%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
MapLight Therapeutics (MPLT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The four lines that matter · FY24–FY25
Revenue ($M)—
0.0
FY24→FY25CAGR —
Net income ($M)▼107.7%
−161.2
FY24→FY25CAGR —
Free cash flow ($M)▼74.2%
−138.6
FY24→FY25CAGR —
Diluted EPS▲82.4%
−18.56
FY24→FY25CAGR —
What the income statement says · FY24–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY24–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.1635, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | YoY | CAGR 24→25 |
|---|---|---|---|---|---|
| Revenue & profitability | |||||
Revenue | — | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | — | — |
Research & development | 215.9 | 138.3 | 68.5 | ▲101.9% | — |
Selling, general & admin | 50.8 | 30.7 | 14.4 | ▲113.1% | — |
Total operating expenses | 266.8 | 169.1 | 82.9 | ▲103.8% | — |
Operating incomefeeds ROC rank | −266.8 | −169.1 | −82.9 | ▼103.8% | — |
Other income, net | 14.7 | 7.9 | 5.4 | — | — |
Pretax income | −252.0 | −161.2 | −77.6 | ▼107.7% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −252.0 | −161.2 | −77.6 | ▼107.7% | — |
| Per share | |||||
Diluted EPSbuyback-sensitive | — | −18.56 | −105.38 | ▲82.4% | — |
Diluted shares (mn) | — | 8.68 | 0.74 | ▲1079.2% | — |
| Margins | |||||
† TTM = trailing four quarters through 2026-09-30.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

